Natural Product (NP) Details
General Information of the NP (ID: NP9453) | |||||
---|---|---|---|---|---|
Name |
Schisandrol A
|
||||
Synonyms |
Schisandrin; Schizandrin; Schizandrol A; 7432-28-2; Wuweizichun A; Wuweizi alcohol A; Schisandrol A; (+)-Schizandrin; 3,4,5,14,15,16-hexamethoxy-9,10-dimethyltricyclo[10.4.0.02,7]hexadeca-1(16),2,4,6,12,14-hexaen-9-ol; Schisandrine; MFCD00905761; Schisandrin,(S); SCHEMBL2702845; CHEBI:80900; DTXSID20995843; AKOS015918158; 1,2,3,10,11,12-hexamethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c][8]annulen-6-ol; AS-17718; DB-055861; FT-0630370; N1884; V1514; C17064; 432S282; Q-100805; 1,2,3,10,11,12-Hexamethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c]cycloocten-6-ol #; Dibenzo(a,c)cycloocten-6-ol, 5,6,7,8-tetrahydro-6,7-dimethyl-1,2 3,10,11,12-hexamethoxy-,stereoisomer
Click to Show/Hide
|
||||
Species Origin | Schisandra chinensis ... | Click to Show/Hide | |||
Schisandra chinensis | |||||
Disease | Hepatocellular carcinoma [ICD-11: 2C12] | Investigative | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C24H32O7
|
||||
PubChem CID | |||||
Canonical SMILES |
CC1CC2=CC(=C(C(=C2C3=C(C(=C(C=C3CC1(C)O)OC)OC)OC)OC)OC)OC
|
||||
InChI |
1S/C24H32O7/c1-13-9-14-10-16(26-3)20(28-5)22(30-7)18(14)19-15(12-24(13,2)25)11-17(27-4)21(29-6)23(19)31-8/h10-11,13,25H,9,12H2,1-8H3
|
||||
InChIKey |
YEFOAORQXAOVJQ-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 7432-28-2
|
||||
ChEBI ID | |||||
Herb ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
Experimental
Result(s) |
SCH acts by affecting the normal formation and functioning of the Pgp-substrate complexes. |